Arcturus Therapeutics Holdings Inc. (ARCT) Financial Statements
Arcturus Therapeutics Holdings Inc. (ARCT) reported trailing twelve-month revenue of $29.4M (down 76.0% year on year) and net income of -$93.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$72.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 279.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.8 | 9.5 | 12.4 | 206.0 | 166.8 | 152.3 | 82.0 | 29.4 | |
| Research & development | 33.6 | 57.8 | 173.8 | 147.8 | 192.1 | 195.2 | 112.2 | 86.8 | |
| Operating income | -25.5 | -71.5 | -202.9 | 12.2 | -78.2 | -95.7 | -76.3 | -102.3 | |
| Pre-tax income | -26.0 | -72.1 | -203.7 | 10.6 | -27.9 | -80.9 | -65.8 | -93.3 | |
| Income tax | — | — | — | 1.3 | 1.8 | -0.0 | — | — | |
| Net income | -26.0 | -72.1 | -203.7 | 9.3 | -29.7 | -80.9 | -65.8 | -93.3 | |
| Diluted EPS ($) | -2.15 | -3.55 | -7.74 | 0.35 | -1.12 | -3.00 | -2.40 | -3.33 | |
| Diluted shares (mn) | — | — | — | 27.1 | 26.6 | 27.0 | 27.4 | — |
USD millions · SEC XBRL
Arcturus Therapeutics Holdings Inc. — questions
- What is Arcturus Therapeutics Holdings Inc.'s revenue?
- $29.4M over the twelve months to 2026-06-30, down 76.0% year on year, from its 10-Q and 10-K filings.
- What is Arcturus Therapeutics Holdings Inc.'s net income?
- -$93.3M over the twelve months to 2026-06-30.
- What is Arcturus Therapeutics Holdings Inc.'s free cash flow?
- -$72.8M over the twelve months to 2026-06-30.
- What are Arcturus Therapeutics Holdings Inc.'s diluted earnings per share?
- $-3.33 over the twelve months to 2026-06-30.
Every figure on this page comes from Arcturus Therapeutics Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.